Trial #	Patent	Type	Petitioner	Status	Filed	Decision
IPR2025-00210	11298349	IPR	Azurity Pharmaceuticals, Inc.	Institution Denied	2024-11-18	2025-06-04
IPR2025-00427	12128039	IPR	Azurity Pharmaceuticals, Inc.	Discretionary Denial	2025-01-09	2025-07-02

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

4 trials from ClinicalTrials.gov — 2 recruiting, 2 active

Trial	Phase	Status	Sponsor	Enrollment	Dates
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors NCT03375320	Phase 3	Active	National Cancer Institute (NCI)	298	2018-10-26 → 2026-08-19
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery NCT05111574	Phase 2	Active	National Cancer Institute (NCI)	101	2022-08-11 → 2026-09-01
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors NCT03866382	Phase 2	Recruiting	National Cancer Institute (NCI)	314	2019-05-13 → 2027-02-28
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study NCT05136196	Phase 2	Recruiting	National Cancer Institute (NCI)	150	2022-12-06 → 2027-01-01

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Medicare Part D Spending

CMS annual spending data for Cometriq (2023)

Total Spending

$3.5M

Total Claims

188

Beneficiaries

Avg Cost/Unit

$250.96

Spending Trend

$8.5M(2019)→$9.1M(2020)→$5.8M(2021)→$4.0M(2022)→$3.5M(2023)

YoY Change:+4.9%

5yr CAGR:+3.1%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain2 active DMFs

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

FERMION OYCABOZANTINIB S-MALATE

DMF 344372020

CHANGZHOU PHARMACEUTICAL FACTORYCABOZANTINIB

DMF 432952025

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

8 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — EQ 20MG BASE

RLD

8 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Nov 29, 2012

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
7579473	Aug 14, 2026	—	Yes	Yes	—	—
8877776	Oct 8, 2030	—	Yes	Yes		—
9717720	Feb 10, 2032	—	—	Yes	—	—
11091439	Jan 15, 2030	—	Yes	—	—	—
11091440	Jan 15, 2030	—	—	Yes	—	—
11098015	Jan 15, 2030	—	—	—		—
11298349	Feb 10, 2032	—	—	Yes	—	—
12128039	Feb 10, 2032	—	—	Yes		—

#002 — EQ 80MG BASE

RLD

8 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Nov 29, 2012